NSF award 2618428 · University of Georgia Research Foundation Inc

Multiplex Next Generation Sequencing of Glycans and Nucleic Acids for Accelerating the Development of Cell Factories and Bioprocesses for Glycoprotein Biomanufacturing

Final report due

28 November 2028

in 772 days · The award ends on 31 July 2028.

GrantClerk is a private service. We are not NSF or any government agency.

Dates this award owes

NSF emails you about this too.

Decide about an extension2 Apr 2028in 532 days
award ending 2028-07-31 · Research.gov
This one is ours, not NSF’s.
Extension request16 Jun 2028in 607 days
award ending 2028-07-31 · Research.gov
PAPPG 24-1: “at least 45 days prior to the end date”
No-cost extension notice21 Jul 2028in 642 days
award ending 2028-07-31 · Research.gov
PAPPG 24-1: “at least ten calendar days prior to the end date”
Final report due28 Nov 2028in 772 days
award ending 2028-07-31 · Research.gov
PAPPG 24-1: “no later than 120-days following the end date of the award”
Project outcomes report due28 Nov 2028in 772 days
award ending 2028-07-31 · Research.gov
PAPPG 24-1: “no later than 120 days following the end date”
Award is closed out28 Nov 2028in 772 days
award ending 2028-07-31 · Research.gov
PAPPG 24-1: “financially closed out 120 days after their expiration date”

Annual report dates come from the budget period on your award notice. That date is not public, so it is not shown here.

How we got this date

NSF lists this award's end date as 31 July 2028.
NSF rules say the final report is due no later than 120 days after that.
So the final report is due by 28 November 2028.

Read the rule on Research.gov

Get a note before each report date

Add this award to your desk. We email you before each date and keep the dates in one place.

Renews each year until you cancel. Cancel any time from your account.

Already a member? Sign in

Award card

Award number: 2618428
Period of support: 15 Feb 2026 – 31 Jul 2028
Amount: $609,503
Awardee: University of Georgia Research Foundation Inc, Athens, GA
Program: Cellular & Biochem Engineering
Directorate: ENG

Abstract

Glycans consist of long branching chains of different sugars. They adorn proteins of all types. Some viruses use glycans to enhance the probability of infection. Some tumors hide from the immune system by using “stealth” glycoproteins on their surfaces. Most of the top drugs by revenue are glycoproteins, and their glycans affect drug safety and efficacy. This places a premium on making sure that their glycans are…

Is this right?

We copy this from the public NSF award record. Your award notice and NSF always win. If a date looks wrong, check Research.gov.